VEGFA and metastatic colorectal cancer: Agents targeting vascular endothelial growth factor family and their receptors (VEGF/R), including anti-VEGFA monoclonal antibodies and a host of receptor tyrosine kinase inhibitors, have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA), first starting with bevacizumab in combination with an intravenous 5-fluorouracil (5-FU)-based chemotherapy regimen for metastatic colorectal cancer [3, 4].